DMG-ACT — Translating Data Into Biological Insight

DMG-ACT (Diffuse Midline Glioma – Adaptive Combinatorial Therapy) is a global, multidisciplinary initiative transforming how children with DIPG and DMG are treated. Built on the belief that no single therapy will defeat these heterogeneous and aggressive tumors, DMG-ACT brings together world-leading clinicians, scientists, and institutions to rapidly identify, test, and advance the most promising treatment combinations for children battling these cancers.

In 2024, DMG-ACT entered a more mature scientific phase, with early survival data and correlative analyses beginning to inform future trial design. Median overall survival in several PNOC022 cohorts compared favorably to historical controls, reinforcing the value of combination-based approaches even as researchers continued to refine therapeutic strategies.

Importantly, 2024 saw the emergence of biomarkers with potential clinical relevance, including ATRX status, age-related differences in outcomes, microbiome signatures, and cerebrospinal fluid metabolomic profiles associated with treatment response. These findings underscored the importance of DMG-ACT’s integrated data strategy and positioned the platform to move toward more personalized, biology-driven therapy selection.

An international DMG-ACT meeting in Madrid further strengthened collaboration, aligning investigators around shared priorities and next-phase expansion.